Table 2.

Data needed to validate phospholipase A2 receptor antibody testing as a diagnostic biomarker for membranous nephropathy

Timing of Phospholipase A2 Receptor Antibody TestingSamples Collected Prior to Kidney Biopsy (Prospective)
PLA2R antibody test characteristicsFurther study of combination testing with ELISA and IFA in larger and more diverse patient populations with nephrotic syndrome
Further study of reference ranges for ELISA
Determine positive and negative predictive values in the population of interest (i.e., nephrotic syndrome)
Improve generalizabilityFurther study of PLA2R antibody testing in larger, more diverse populations with additional medical problems, including those traditionally associated with “secondary” membranous nephropathy
Algorithm for clinical use of PLA2R antibody testingRequires validation in other prospective cohorts of patients with nephrotic syndrome
  • PLA2R, phospholipase A2 receptor; IFA, immunofluorescence assay.